The University of Oxford is part of a £15.9 million UK-wide programme to develop human tumour tissue models, improving cancer research, accelerating drug discovery and reducing reliance on animal testing.
Phillip P. Chan, MD, PhD, Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO), discusses the use of CytoSorb, a broad-spectrum blood purification technology to treat cytokine storm and hyperinflammation in critically ill COVID-19 patients.
The independent experts of the FDA say the Pfizer vaccine is good to go, which means that the COVID vaccine should be formally approved in a matter of days.
In this interview, Prof Christophe Drouet (CNRS Senior Scientist) – an international specialist in bio-inspired apatites – relates the multifunctional potential of these intrinsically biocompatible compounds for a wealth of uses from bone tissue repair, to cell-scale medicine.
Here, we look into the many ways in which medical and safety technology manufacturer Dräger has been stepping up to help its customers through the COVID-19 crisis.
Andrea Ammon, Director at the European Centre for Disease Prevention and Control, takes us on a journey from COVID-19 to the future of public health surveillance.
Dr Ganesan Baranidharan, consultant in anaesthesia and pain medicine at the Leeds Teaching Hospitals NHS Trust, explains the power of neuromodulation for managing chronic pain and explains why comprehensive evidence is needed.
Leading pancreatic cancer experts Professor Matthias Löhr and Professor Monique van Leerdam of United European Gastroenterology’s (UEG) Public Affairs Committee discuss the importance of early diagnosis and the latest developments in treatment for pancreatic cancer.
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Fintan Grant, NHS Digital’s Programme Head for Medicines and Pharmacy charts the recent change in the speed of healthcare delivery in light of COVID-19 including the importance of digital solutions.
Eight days after the Pfizer vaccine results (90% effective) brought collective hope to the world, the Moderna vaccine has proven to be 95% effective at fighting COVID-19.
